Introduction: Hidradenitis suppurativa (HS) is a chronic inflammatory skin disease for which certain risk factors are well known: obesity and smoking (in particular). However, the factors associated with more severe conditions, and therefore potential aggravators of the disease, remain a matter of debate. Our study aims to determine the clinical factors associated with severe HS using several severity scores. Methods: The data were obtained via the ERHS questionnaire from patients exclusively recruited at Erasme Hospital in Brussels. The severity of HS was firstly estimated by the Hurley score, and secondly by a metascore, a system combining the iHS4, HS-PGA, SAHS, and DLQI. Univariable and multivariable analyses were performed. Results: Six hundred and forty-seven patients were included in the Hurley analysis, and 456 patients in the metascore analysis. In multivariable analysis, men have a more severe metascore than women (odds ratio [OR] = 1.89, p = 0.022), smoking was associated with a more severe disease according to metascore, especially in mild cases (OR = 0.76, p = 0.043), and an elevated body mass index was associated with having Hurley stage III disease compared to Hurley I or II disease (OR = 1.09, p = 0.001). A significant association is also shown between blood pressure and Hurley stage (OR = 0.97, p = 0.025). Self-reports of nonsteroidal anti-inflammatory drugs aggravating the disease is also a factor associated with greater severity according to the metascore (OR = 0.12, p = 0.008). Finally, several locations of HS lesions were associated with greater severity, in particular the armpits according to the metascore (OR = 0.29, p < 0.001), and the perianal area according to the Hurley score (OR = 0.15, p < 0.001). Conclusion: HS seems to be more severe in men; smoking seems to aggravate mild cases of HS, while increased body mass index plays a major role in the transition from Hurley II to Hurley III.

1.
White
JML
,
Lui
H
,
Chute
CG
,
Jakob
R
,
Chalmers
RJG
.
The WHO ICD-11 classification of dermatological diseases: a new comprehensive online skin disease taxonomy designed by and for dermatologists
.
Br J Dermatol
.
2022
;
186
(
1
):
178
9
.
2.
ED92.0 Hidradenitis suppurativa - ICD-11 mms [Internet]. [cited 4 nov 2023]. Available from: https://www.findacode.com/icd-11/code-1621794154.html
3.
Fimmel
S
,
Zouboulis
CC
.
Comorbidities of hidradenitis suppurativa (acne inversa)
.
Dermatoendocrinol
.
2010
;
2
(
1
):
9
16
.
4.
Daxhelet
M
,
Suppa
M
,
White
J
,
Benhadou
F
,
Thorlacius
LR
,
Jemec
GBE
, et al
.
Proposed definitions of typical lesions in hidradenitis suppurativa
.
Dermatology
.
2020
;
236
(
5
):
431
8
.
5.
Kimball
AB
,
Sundaram
M
,
Gauthier
G
,
Guérin
A
,
Pivneva
I
,
Singh
R
, et al
.
The comorbidity burden of hidradenitis suppurativa in the United States: a claims data analysis
.
Dermatol Ther
.
2018
;
8
(
4
):
557
69
.
6.
Jfri
A
,
Nassim
D
,
O’Brien
E
,
Gulliver
W
,
Nikolakis
G
,
Zouboulis
CC
.
Prevalence of hidradenitis suppurativa: a systematic review and meta-regression analysis
.
JAMA Dermatol
.
2021
;
157
(
8
):
924
31
.
7.
Sabat
R
,
Jemec
GBE
,
Matusiak
Ł
,
Kimball
AB
,
Prens
E
,
Wolk
K
.
Hidradenitis suppurativa
.
Nat Rev Dis Primers
.
2020
;
6
(
1
):
18
.
8.
Cazzaniga
S
,
Pezzolo
E
,
Garcovich
S
,
Naldi
L
,
Bettoli
V
,
Abeni
D
, et al
.
Late-onset hidradenitis suppurativa: a cluster analysis of the National Italian Registry IRHIS
.
J Am Acad Dermatol
.
2021
;
85
(
1
):
e29
32
.
9.
Goldburg
SR
,
Strober
BE
,
Payette
MJ
.
Hidradenitis suppurativa: epidemiology, clinical presentation, and pathogenesis
.
J Am Acad Dermatol
.
2020
;
82
(
5
):
1045
58
.
10.
Sabat
R
,
Chanwangpong
A
,
Schneider-Burrus
S
,
Metternich
D
,
Kokolakis
G
,
Kurek
A
, et al
.
Increased prevalence of metabolic syndrome in patients with acne inversa
.
PLoS One
.
2012
;
7
(
2
):
e31810
.
11.
Sartorius
K
,
Emtestam
L
,
Jemec
GBE
,
Lapins
J
.
Objective scoring of hidradenitis suppurativa reflecting the role of tobacco smoking and obesity
.
Br J Dermatol
.
2009
;
161
(
4
):
831
9
.
12.
Shalom
G
,
Freud
T
,
Harman-Boehm
I
,
Polishchuk
I
,
Cohen
AD
.
Hidradenitis suppurativa and metabolic syndrome: a comparative cross-sectional study of 3207 patients
.
Br J Dermatol
.
2015
;
173
(
2
):
464
70
.
13.
Bettoli
V
,
Naldi
L
,
Cazzaniga
S
,
Zauli
S
,
Atzori
L
,
Borghi
A
, et al
.
Overweight, diabetes and disease duration influence clinical severity in hidradenitis suppurativa-acne inversa: evidence from the national Italian registry
.
Br J Dermatol
.
2016
;
174
(
1
):
195
7
.
14.
Malara
A
,
Hughes
R
,
Jennings
L
,
Sweeney
CM
,
Lynch
M
,
Awdeh
F
, et al
.
Adipokines are dysregulated in patients with hidradenitis suppurativa
.
Br J Dermatol
.
2018
;
178
(
3
):
792
3
.
15.
van Straalen
KR
,
Schneider-Burrus
S
,
Prens
EP
.
Current and future treatment of hidradenitis suppurativa
.
Br J Dermatol
.
2020
;
183
(
6
):
e178-87
.
16.
Nguyen
TV
,
Damiani
G
,
Orenstein
LV
,
Hamzavi
I
,
Jemec
GB
.
Hidradenitis suppurativa: an update on epidemiology, phenotypes, diagnosis, pathogenesis, comorbidities and quality of life
.
J Eur Acad Dermatol Venereol
.
2021
;
35
(
1
):
50
61
.
17.
Scala
E
,
Cacciapuoti
S
,
Garzorz-Stark
N
,
Megna
M
,
Marasca
C
,
Seiringer
P
, et al
.
Hidradenitis suppurativa: where we are and where we are going
.
Cells
.
2021
;
10
(
8
):
2094
.
18.
Kelly
G
,
Prens
EP
.
Inflammatory mechanisms in hidradenitis suppurativa
.
Dermatol Clin
.
2016
;
34
(
1
):
51
8
.
19.
Thompson
KG
,
Shuster
M
,
Ly
BC
,
Antonescu
C
,
Florea
L
,
Chien
AL
, et al
.
Variability in skin microbiota between smokers, former smokers, and nonsmokers
.
J Am Acad Dermatol
.
2020
;
83
(
3
):
942
4
.
20.
Wark
KJL
,
Cains
GD
.
The microbiome in hidradenitis suppurativa: a review
.
Dermatol Ther
.
2021
;
11
(
1
):
39
52
.
21.
Melnik
BC
,
Plewig
G
.
Impaired Notch-MKP-1 signalling in hidradenitis suppurativa: an approach to pathogenesis by evidence from translational biology
.
Exp Dermatol
.
2013
;
22
(
3
):
172
7
.
22.
Napolitano
M
,
Megna
M
,
Timoshchuk
EA
,
Patruno
C
,
Balato
N
,
Fabbrocini
G
, et al
.
Hidradenitis suppurativa: from pathogenesis to diagnosis and treatment
.
Clin Cosmet Investig Dermatol
.
2017
;
10
:
105
15
.
23.
Ingram
JR
,
Piguet
V
.
Phenotypic heterogeneity in hidradenitis suppurativa (acne inversa): classification is an essential step toward personalized therapy
.
J Invest Dermatol
.
2013
;
133
(
6
):
1453
6
.
24.
Canoui-Poitrine
F
,
Le Thuaut
A
,
Revuz
JE
,
Viallette
C
,
Gabison
G
,
Poli
F
, et al
.
Identification of three hidradenitis suppurativa phenotypes: latent class analysis of a cross-sectional study
.
J Invest Dermatol
.
2013
;
133
(
6
):
1506
11
.
25.
Heudens
S
,
Sarkis
AS
,
Daoud
M
,
Daxhelet
M
,
Benhadou
F
,
Suppa
M
, et al
.
Belgian patients of the European Registry for Hidradenitis Suppurativa (ERHS-Be): data, scores, and phenotypes since 2015
.
Dermatology
.
2024
;
240
(
4
):
553
64
.
26.
Martorell-Calatayud
A
,
Sanz-Motilva
V
,
Alfaro-Rubio
A
,
Parra-Uribe
M
,
Garcia-Melgares
ML
,
Pelufo
C
, et al
.
Phenotypic heterogeneity in hidradenitis suppurativa
.
J Am Acad Dermatol
.
2015
;
72
(
5
):
AB150
.
27.
Martorell
A
,
Jfri
A
,
Koster
SBL
,
Gomez‐Palencia
P
,
Solera
M
,
Alfaro‐Rubio
A
, et al
.
Defining hidradenitis suppurativa phenotypes based on the elementary lesion pattern: results of a prospective study
.
J Eur Acad Dermatol Venereol
.
2020
;
34
(
6
):
1309
18
.
28.
Naasan
H
,
Affleck
A
.
Atypical hidradenitis suppurativa
.
Clin Exp Dermatol
.
2015
;
40
(
8
):
891
3
.
29.
van der Zee
HH
,
Jemec
GBE
.
New insights into the diagnosis of hidradenitis suppurativa: clinical presentations and phenotypes
.
J Am Acad Dermatol
.
2015
;
73
(
5 Suppl 1
):
S23
26
.
30.
Dudink
K
,
Aarts
P
,
Ardon
C
,
Vossen
A
,
Koster
S
,
Van den Bosch
JF
, et al
.
Prevalence and clinical characteristics of hidradenitis suppurativa phenotypes in a large Dutch cohort
.
Dermatology
.
2021
;
238
:
600
2
.
31.
Frew
JW
,
Hawkes
JE
,
Sullivan-Whalen
M
,
Gilleaudeau
P
,
Krueger
JG
.
Inter-rater reliability of phenotypes and exploratory genotype-phenotype analysis in inherited hidradenitis suppurativa
.
Br J Dermatol
.
2019
;
181
(
3
):
566
71
.
32.
Thorlacius
L
,
Riis
PT
,
List
EK
,
Christensen
R
,
Jemec
GBE
.
Sub-classification of Hidradenitis suppurativa: a cross-sectional study
.
Arch Dermatol Res
.
2022
;
314
(
2
):
207
12
.
33.
Cazzaniga
S
,
Pezzolo
E
,
Bettoli
V
,
Abeni
D
,
Marzano
AV
,
Patrizi
A
, et al
.
Characterization of hidradenitis suppurativa phenotypes: a multidimensional latent class analysis of the national Italian registry IRHIS
.
J Invest Dermatol
.
2021
;
141
(
5
):
1236
42.e1
.
34.
González-Manso
A
,
Agut-Busquet
E
,
Romaní
J
,
Vilarrasa
E
,
Bittencourt
F
,
Mensa
A
, et al
.
Hidradenitis suppurativa: proposal of classification in two endotypes with two-step cluster analysis
.
Dermatology
.
2021
;
237
(
3
):
365
71
.
35.
Hristakieva
E
,
Manuelyan
K
,
Gancheva
T
,
Lavcheva
R
,
Deliyska
R
.
Hidradenitis suppurativa from the typical patient to the new clinical phenotypes
.
Clin Dermatol
.
2023
;
41
(
15
):
584
91
.
36.
Jastrząb
B
,
Szepietowski
JC
,
Matusiak
Ł
.
Hidradenitis suppurativa and follicular occlusion syndrome: where is the pathogenetic link
.
Clin Dermatol
.
2023
;
41
(
5
):
576
83
.
37.
Garcovich
S
,
Genovese
G
,
Moltrasio
C
,
Malvaso
D
,
Marzano
AV
.
PASH, PAPASH, PsAPASH, and PASS: the autoinflammatory syndromes of hidradenitis suppurativa
.
Clin Dermatol
.
2021
;
39
(
2
):
240
7
.
38.
Egeberg
A
,
Gislason
GH
,
Hansen
PR
.
Risk of major adverse cardiovascular events and all-cause mortality in patients with hidradenitis suppurativa
.
JAMA Dermatol
.
2016
;
152
(
4
):
429
34
.
39.
Cartron
A
,
Driscoll
MS
.
Comorbidities of hidradenitis suppurativa: a review of the literature
.
Int J Womens Dermatol
.
2019
;
5
(
5
):
330
4
.
40.
Garg
A
,
Neuren
E
,
Strunk
A
.
Hidradenitis suppurativa is associated with polycystic ovary syndrome: a population-based analysis in the United States
.
J Invest Dermatol
.
2018
;
138
(
6
):
1288
92
.
41.
Chen
WT
,
Chi
CC
.
Association of hidradenitis suppurativa with inflammatory bowel disease: a systematic review and meta-analysis
.
JAMA Dermatol
.
2019
;
155
(
9
):
1022
7
.
42.
Shalom
G
,
Freud
T
,
Ben Yakov
G
,
Khoury
R
,
Dreiher
J
,
Vardy
DA
, et al
.
Hidradenitis suppurativa and inflammatory bowel disease: a cross-sectional study of 3,207 patients
.
J Invest Dermatol
.
2016
;
136
(
8
):
1716
8
.
43.
Garg
A
,
Malviya
N
,
Strunk
A
,
Wright
S
,
Alavi
A
,
Alhusayen
R
, et al
.
Comorbidity screening in hidradenitis suppurativa: evidence-based recommendations from the US and Canadian hidradenitis suppurativa foundations
.
J Am Acad Dermatol
.
2022
;
86
(
5
):
1092
101
.
44.
Lee
HH
,
Patel
KR
,
Singam
V
,
Rastogi
S
,
Silverberg
JI
.
Associations of cutaneous and extracutaneous infections with hidradenitis suppurativa in U.S. children and adults
.
Br J Dermatol
.
2020
;
182
(
2
):
327
34
.
45.
Nielsen
VW
,
Jørgensen
AHR
,
Thomsen
SF
.
Fatal outcome of malignant transformation of hidradenitis suppurativa: a case report and literature review
.
Clin Case Rep
.
2020
;
8
(
3
):
504
7
.
46.
Shlyankevich
J
,
Chen
AJ
,
Kim
GE
,
Kimball
AB
.
Hidradenitis suppurativa is a systemic disease with substantial comorbidity burden: a chart-verified case-control analysis
.
J Am Acad Dermatol
.
2014
;
71
(
6
):
1144
50
.
47.
Huilaja
L
,
Tiri
H
,
Jokelainen
J
,
Timonen
M
,
Tasanen
K
.
Patients with hidradenitis suppurativa have a high psychiatric disease burden: a Finnish nationwide registry study
.
J Invest Dermatol
.
2018
;
138
(
1
):
46
51
.
48.
Misitzis
A
,
Stratigos
AJ
,
Beatson
M
,
Mastorakos
G
,
Dellavalle
RP
,
Weinstock
MA
,
The association of metformin use with keratinocyte carcinoma development in high-risk patients
.
Dermatol Ther
.
2020
;
33
(
6
):
e14402
.
49.
Phan
K
,
Huo
YR
,
Smith
SD
.
Hidradenitis suppurativa and psychiatric comorbidities, suicides and substance abuse: systematic review and meta-analysis
.
Ann Transl Med
.
2020
;
8
(
13
):
821
.
50.
Daxhelet
M
,
Suppa
M
,
Benhadou
F
,
Djamei
V
,
Tzellos
T
,
Ingvarsson
G
, et al
.
Establishment of a European Registry for hidradenitis suppurativa/acne inversa by using an open source software
.
J Eur Acad Dermatol Venereol
.
2016
;
30
(
8
):
1424
6
.
51.
Daxhelet
M
,
Daoud
M
,
Suppa
M
,
Benhadou
F
,
Njimi
H
,
Tzellos
T
, et al
.
European registry for hidradenitis suppurativa: state of play
.
J Eur Acad Dermatol Venereol
.
2021
;
35
(
4
):
e274-6
.
52.
DeMers
D
,
Wachs
D
.
Physiology, mean arterial pressure
.
StatPearls [internet]
.
Treasure Island (FL)
:
StatPearls Publishing
;
2023
. [cited 16 Nov 2023]. Available from: http://www.ncbi.nlm.nih.gov/books/NBK538226/
53.
Daoud
M
,
Benhadou
F
,
Njimi
H
,
Jemec
GBE
,
Daxhelet
M
,
White
J
, et al
.
Scoring hidradenitis suppurativa: how to simplify data collection
.
J Eur Acad Dermatol Venereol
.
2022
;
37
(
4
):
e562
4
.
54.
Hurley
HJ
.
Axillary hyperhidrosis, apocrine bromhidrosis, hidradenitis suppurativa and familial benign pemphigus: surgical approach
.
Dermatol Surg
.
1989
:
729
39
.
55.
Daoud
M
,
Njimi
H
,
Benhadou
F
,
Suppa
M
,
Daxhelet
M
,
Karama
J
, et al
.
Metascoring hidradenitis suppurativa
.
J Eur Acad Dermatol Venereol
.
2021
;
35
(
4
):
e272-4
.
56.
Zouboulis
CC
,
Tzellos
T
,
Kyrgidis
A
,
Jemec
GBE
,
Bechara
FG
,
Giamarellos-Bourboulis
EJ
, et al
.
Development and validation of the International Hidradenitis Suppurativa Severity Score System (IHS4), a novel dynamic scoring system to assess HS severity
.
Br J Dermatol
.
2017
;
177
(
5
):
1401
9
.
57.
Kimball
AB
,
Kerdel
F
,
Adams
D
,
Mrowietz
U
,
Gelfand
JM
,
Gniadecki
R
, et al
.
Adalimumab for the treatment of moderate to severe Hidradenitis suppurativa: a parallel randomized trial
.
Ann Intern Med
.
2012
;
157
(
12
):
846
55
.
58.
Hessam
S
,
Scholl
L
,
Sand
M
,
Schmitz
L
,
Reitenbach
S
,
Bechara
FG
.
A novel severity assessment scoring system for hidradenitis suppurativa
.
JAMA Dermatol
.
2018
;
154
(
3
):
330
5
.
59.
Finlay
AY
,
Khan
GK
.
Dermatology Life Quality Index (DLQI): a simple practical measure for routine clinical use
.
Clin Exp Dermatol
.
1994
;
19
(
3
):
210
6
.
60.
Saunte
DML
,
Jemec
GBE
.
Hidradenitis suppurativa: advances in diagnosis and treatment
.
JAMA
.
2017
;
318
(
20
):
2019
32
.
61.
Revuz
J
.
Évaluation clinique de la sévérité de l’hidradénite suppurée: maladie de Verneuil
.
Ann Dermatol Venereol
.
2015
;
142
(
12
):
729
35
.
62.
Daoud
M
,
Suppa
M
,
Benhadou
F
,
Daxhelet
M
,
Njimi
H
,
White
J
, et al
.
Overview and comparison of the clinical scores in hidradenitis suppurativa: a real-life clinical data
.
Front Med
.
2023
;
10
:
1145152
.
63.
Schrader
AMR
,
Deckers
IE
,
van der Zee
HH
,
Boer
J
,
Prens
EP
.
Hidradenitis suppurativa: a retrospective study of 846 Dutch patients to identify factors associated with disease severity
.
J Am Acad Dermatol
.
2014
;
71
(
3
):
460
7
.
64.
Matusiak
L
,
Bieniek
A
,
Szepietowski
JC
.
Hidradenitis suppurativa and associated factors: still unsolved problems
.
J Am Acad Dermatol
.
2009
;
61
(
2
):
362
5
.
65.
Grimstad
Ø
,
Tzellos
T
,
Dufour
DN
,
Bremnes
Ø
,
Skoie
IM
,
Snekvik
I
, et al
.
Evaluation of medical and surgical treatments for hidradenitis suppurativa using real-life data from the Scandinavian registry (HISREG)
.
J Eur Acad Dermatol Venereol
.
2019
;
33
(
6
):
1164
71
.
66.
Shih
T
,
Seivright
JR
,
McKenzie
SA
,
Harview
CL
,
Truong
AK
,
Shi
VY
, et al
.
Gender differences in hidradenitis suppurativa characteristics: a retrospective cohort analysis
.
Int J Womens Dermatol
.
2021
;
7
(
5Part B
):
672
4
.
67.
Hammud
A
,
Avitan-Hersh
E
,
Khamaysi
Z
.
Clinical-epidemiological characteristics of hidradenitis suppurativa: a retrospective cohort study from a tertiary care centre in northern Israel
.
J Clin Med
.
2023
;
12
(
12
):
3921
.
68.
Napolitano
M
,
Mastroeni
S
,
Fusari
R
,
Mazzanti
C
,
Ciccone
D
,
Pallotta
S
, et al
.
The International Hidradenitis Suppurativa Severity Score System (IHS4) is a valuable tool to assess sex- and gender-associated differences
.
Eur J Dermatol
.
2020
;
30
(
2
):
201
3
.
69.
Canoui-Poitrine
F
,
Revuz
JE
,
Wolkenstein
P
,
Viallette
C
,
Gabison
G
,
Pouget
F
, et al
.
Clinical characteristics of a series of 302 French patients with hidradenitis suppurativa, with an analysis of factors associated with disease severity
.
J Am Acad Dermatol
.
2009
;
61
(
1
):
51
7
.
70.
Chandran
NS
,
Lee
JH
,
Kurokawa
I
.
Hidradenitis suppurativa in south-east asia and east asia
.
Exp Dermatol
.
2021
;
30
(
Suppl 1
):
23
6
.
71.
Sayed
CJ
,
Hsiao
JL
,
Okun
MM
;
Hidradenitis Suppurativa Foundation Women's Health Subcommittee
.
Clinical epidemiology and management of hidradenitis suppurativa
.
Obstet Gynecol
.
2021
;
137
(
4
):
731
46
.
72.
Boer
J
.
Resolution of hidradenitis suppurativa after weight loss by dietary measures, especially on frictional locations
.
J Eur Acad Dermatol Venereol
.
2016
;
30
(
5
):
895
6
.
73.
Gold
DA
,
Reeder
VJ
,
Mahan
MG
,
Hamzavi
IH
.
The prevalence of metabolic syndrome in patients with hidradenitis suppurativa
.
J Am Acad Dermatol
.
2014
;
70
(
4
):
699
703
.
74.
Seyed Jafari
SM
,
Knüsel
E
,
Cazzaniga
S
,
Hunger
RE
.
A retrospective cohort study on patients with hidradenitis suppurativa
.
Dermatology
.
2018
;
234
(
1–2
):
71
8
.
75.
Dessinioti
C
,
Zisimou
C
,
Tzanetakou
V
,
Ntritsos
G
,
Kontochristopoulos
G
,
Antoniou
C
.
A retrospective institutional study of the association of smoking with the severity of hidradenitis suppurativa
.
J Dermatol Sci
.
2017
;
87
(
2
):
206
7
.
76.
Fernandez
JM
,
Rizvi
OH
,
Marr
KD
,
Hendricks
AJ
,
Maarouf
M
,
Price
KN
, et al
.
Topography of lesion progression in hidradenitis suppurativa
.
Int J Dermatol
.
2021
;
60
(
8
):
e323-5
.
77.
Horváth
B
,
Janse
IC
,
Sibbald
GR
.
Pain management in patients with hidradenitis suppurativa
.
J Am Acad Dermatol
.
2015
;
73
(
5 Suppl 1
):
S47
51
.
78.
Savage
KT
,
Singh
V
,
Patel
ZS
,
Yannuzzi
CA
,
McKenzie-Brown
AM
,
Lowes
MA
, et al
.
Pain management in hidradenitis suppurativa and a proposed treatment algorithm
.
J Am Acad Dermatol
.
2021
;
85
(
1
):
187
99
.
79.
Horváth
B
,
Janse
IC
,
Blok
JL
,
Driessen
RJB
,
Boer
J
,
Mekkes
JR
, et al
.
Hurley staging refined: a proposal by the Dutch hidradenitis suppurativa expert group
.
Acta Derm Venerol
.
2017
;
97
(
3
):
412
13
.
80.
Kirby
JS
,
Thorlacius
L
,
Villumsen
B
,
Ingram
JR
,
Garg
A
,
Christensen
KB
, et al
.
The Hidradenitis Suppurativa Quality of Life (HiSQOL) score: development and validation of a measure for clinical trials
.
Br J Dermatol
.
2019
;
183
(
2
):
340
8
.
81.
Marrón
SE
,
Gómez-Barrera
M
,
Tomás-Aragonés
L
,
Díaz Díaz
RM
,
Vilarrasa Rull
E
,
Madrid Álvarez
MB
, et al
.
Development and preliminary validation of the HSQoL-24 tool to assess quality of life in patients with hidradenitis suppurativa
.
Actas Dermosifiliogr
.
2019
;
110
(
7
):
554
60
.
82.
Chiricozzi
A
,
Bettoli
V
,
De Pità
O
,
Dini
V
,
Fabbrocini
G
,
Monfrecola
G
, et al
.
HIDRAdisk: an innovative visual tool to assess the burden of hidradenitis suppurativa
.
J Eur Acad Dermatol Venereol
.
2019
;
33
(
1
):
e24
6
.
You do not currently have access to this content.